Pandemic Will Limit Role Of US FDA Inspections In Driving FY 2021 Drug GMP Sanctions
Executive Summary
Look for alternative approaches like sample testing, remote records review and reliance on trusted host nation authorities to fill many inspection gaps – except for OAI re-inspections. Meanwhile, post-emergency planning begins.
You may also be interested in...
US FDA Mulls Advance Notice On Domestic Surveillance Inspections Post-COVID
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.
US FDA Mulls Possibility Of Preannouncing Post-COVID Domestic Surveillance Inspections
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.
US FDA To Share Remote Assessment Findings And Mull Replies Before Issuing Complete Responses
No more letters derailing applications over surprise drug GMP issues raised in remote records reviews, agency says. Now if sponsors get these CRLs, they will already know why.